1-3 of 3
Arlene A. Forastiere
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3708: Phase II study of panitumumab plus irinotecan as second-line therapy for advanced esophageal adenocarcinoma

Yang Liu, Ali H. Zaidi, Katie S. Nason, Ann M. Egloff, Robert Ferris, Blair Jobe, Harry Yoon, Arlene A. Forastiere, Michael K. Gibson
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3708.
https://doi.org/10.1158/1538-7445.AM2012-3708
Published: 15 April 2012
View articletitled, Abstract 3708: Phase II study of panitumumab plus irinotecan as second-line therapy for advanced esophageal adenocarcinoma
Journal Articles

Phase I and Pharmacokinetic Study of Hepsulfam (NSC 329680)

Carolyn B. Hendricks, Louise B. Grochow, Eric K. Rowinsky, Arlene A. Forastiere, William P. McGuire, David S. Ettinger, Susan Sartorius, Barbara Lubejko, Ross C. Donehower
Journal: Cancer Research
Cancer Res (1991) 51 (21): 5781–5785.
Published: 01 November 1991
View articletitled, Phase I and Pharmacokinetic Study of Hepsulfam (NSC 329680)
Open the PDF for Phase I and Pharmacokinetic Study of Hepsulfam (NSC 329680) in another window
Journal Articles

Pharmacokinetic and Toxicity Evaluation of Five-Day Continuous Infusion versus Intermittent Bolus cis-Diamminedichloroplatinum(II) in Head and Neck Cancer Patients

Arlene A. Forastiere, James F. Belliveau, Marshall P. Goren, Walter C. Vogel, Marshall R. Posner, Gerard P. O'Leary, Jr.
Journal: Cancer Research
Cancer Res (1988) 48 (13): 3869–3874.
Published: 01 July 1988
View articletitled, Pharmacokinetic and Toxicity Evaluation of Five-Day Continuous Infusion versus Intermittent Bolus cis-Diamminedichloroplatinum(II) in Head and Neck Cancer Patients
Open the PDF for Pharmacokinetic and Toxicity Evaluation of Five-Day Continuous Infusion versus Intermittent Bolus cis-Diamminedichloroplatinum(II) in Head and Neck Cancer Patients in another window